The 5th edition of the Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients has been postponed until 2018.
This workshop, previously known as International Workshop on Optimal Use of DAAs in Advanced Liver Disease and Transplantation focuses on current and emerging direct-acting antivirals (DAAs) which promise to impact greatly the management of hepatitis C both prior to and after transplantation. Patients with cirrhosis, patients on waiting lists for liver transplantation, and liver recipients represent populations with the greatest need for effective new therapies. Certainly investigators have the possibility to submit their research in this area to major international conferences, but there is usually limited time for in-depth discussion and debate among experts on new data and their implications.
The target audience of this meeting consists of gastroenterologists/hepatologists, pharmacologists, drug development experts, virologists, immunologists, young investigators and other experts involved in liver transplantation.
The format will be a one-day program with invited lectures, panel discussions and case presentations. We will emphasize the nature of the meeting and allocate much of discussion time for Q&A sessions and roundtable discussions. The workshop will assemble researchers and clinicians in order to allow presentation and discussion of the latest developments in an open environment.
We hope you will be joining us this year and we look forward to welcoming you to the workshop in 2018!